Wegovy has just had its first weight-loss pill licensed for use in the UK to much fanfare. The GLP-1 medication was previously only available as an injection; the semaglutide tablets are expected to become available via private providers, including supermarkets and pharmacies, within the next few weeks.
Eligible candidates will be adults with a BMI of 30 or more, or adults with a BMI of 27 or more and at least one co-morbidity, such as high blood pressure, type 2 diabetes or cardiovascular disease.
